Holocene Advisors, LP Novo Cure LTD Transaction History

Holocene Advisors, LP

$31.7 Billion
Q1 2025

A detailed history of Holocene Advisors, LP transactions in Novo Cure LTD stock. As of the latest transaction made, Holocene Advisors, LP holds 11,979 shares of NVCR stock, worth $214,543. This represents 0.0% of its overall portfolio holdings.

Number of Shares

11,979

Previous 39,942 70.01%

Holding current value

$214,543

Previous $1.19 Million 82.1%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$17.82 - $30.19 $498,300 - $844,202	-27,963 Reduced 70.01%	11,979 $213,000
Q4 2024 Feb 14, 2025	SELL	$14.54 - $33.41 $498,809 - $1.15 Million	-34,306 Reduced 46.2%	39,942 $1.19 Million
Q3 2024 Nov 14, 2024	BUY	$15.61 - $23.34 $347,728 - $519,921	22,276 Added 42.86%	74,248 $1.16 Million
Q2 2024 Aug 14, 2024	SELL	$11.83 - $24.05 $1.39 Million - $2.82 Million	-117,445 Reduced 69.32%	51,972 $890,000
Q1 2024 May 15, 2024	BUY	$12.42 - $17.29 $48,673 - $67,759	3,919 Added 2.37%	169,417 $2.65 Million
Q4 2023 Feb 14, 2024	SELL	$11.13 - $15.78 $860,794 - $1.22 Million	-77,340 Reduced 31.85%	165,498 $2.47 Million
Q3 2023 Nov 14, 2023	BUY	$16.15 - $42.35 $3.92 Million - $10.3 Million	242,838 New	242,838 $3.92 Million
Q2 2022 Aug 15, 2022	SELL	$56.6 - $89.9 $1.2 Million - $1.91 Million	-21,202 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$60.15 - $84.52 $1.28 Million - $1.79 Million	21,202 New	21,202 $1.76 Million
Q4 2020 Feb 16, 2021	SELL	$112.16 - $174.14 $649,742 - $1.01 Million	-5,793 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$58.05 - $111.31 $336,283 - $644,818	5,793 New	5,793 $645,000

Others Institutions Holding NVCR

# of Institutions

266

Shares Held

79.4M

Call Options Held

970K

Put Options Held

118K

View Full List

About NovoCure Ltd

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $1.88B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

More about NVCR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Holocene Advisors, LP, based on Form 13F filings with the SEC.

News

Stay updated on Holocene Advisors, LP with notifications on news.

Account

Holocene Advisors, LP Novo Cure LTD Transaction History